Patent Owner Prevails In Final Written Decision By Patent Board

(January 11, 2018, 4:32 PM EST) -- ALEXANDRIA, Va. — A patent relating to Novartis AG’s Afinitor anti-cancer drug was confirmed as patentable Jan. 11 in a final written decision by the Patent Trial and Appeal Board, which rebuffed allegations of obviousness by Par Pharmaceutical Inc. and other drug makers (Par Pharmaceutical Inc., et al., v. Novartis AG, No. IPR2016-00084, PTAB)....

Attached Documents

Related Sections